Circulating microRNA146b‐5p is superior to C‐reactive protein as a novel biomarker for monitoring inflammatory bowel disease

Chen, Peng; Liu, Ying; Li, Li; Yu, Qiao; Chao, Kang; Zhou, Gaoshi; Qiu, Yun; Feng, Rui; Huang, Shanshan; He, Yao; Chen, Baili; Chen, Minhu; Zeng, Zhirong; Zhang, Shenghong

doi:10.1111/apt.15159

Cited by 34 publications

(25 citation statements)

References 56 publications

(60 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 24 , 25 Circulating miR-146b has previously been described as a monitoring biomarker for IBD, correlating highly with endoscopic disease activity and with more specificity than serum C-reactive protein. 26 …”

Section: Discussionmentioning

confidence: 99%

Serum miRNAs Are Pharmacodynamic Biomarkers Associated With Therapeutic Response in Pediatric Inflammatory Bowel Disease

Batra

Heier

Diaz-Calderon

et al. 2020

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

Background We sought to identify microRNAs (miRNAs) associated with response to anti-TNF-α or glucocorticoids in children with inflammatory bowel disease (IBD) to generate candidate pharmacodynamic and monitoring biomarkers. Methods Clinical response was assessed by Pediatric Crohn’s Disease Activity Index and Pediatric Ulcerative Colitis Activity Index. Quantitative real-time polymerase chain reaction via Taqman Low-Density Array cards were used to identify miRNAs in a discovery cohort of responders (n = 11) and nonresponders (n = 8). Seven serum miRNAs associated with clinical response to treatment, along with 4 previously identified (miR-146a, miR-146b, miR-320a, miR-486), were selected for further study. Candidates were assessed in a validation cohort of serum samples from IBD patients pre- and post-treatment and from healthy controls. Expression of miRNA was also analyzed in inflamed mucosal biopsies from IBD patients and non-IBD controls. Results Discovery cohort analysis identified 7 miRNAs associated with therapeutic response: 5 that decreased (miR-126, miR-454, miR-26b, miR-26a, let-7c) and 2 that increased (miR-636, miR-193b). In the validation cohort, 7 of 11 candidate miRNAs changed in the same direction with response to anti-TNF-α therapies, glucocorticoids, or both. In mucosal biopsies, 7 out of 11 miRNAs were significantly increased in IBD vs healthy controls. Conclusions Five candidate miRNAs associated with clinical response and mucosal inflammation in pediatric IBD patients were identified (miR-126, let-7c, miR-146a, miR-146b, and miR-320a). These miRNAs may be further developed as pharmacodynamic and response monitoring biomarkers for use in clinical care and trials.

show abstract

Section: Discussionmentioning

confidence: 99%

Serum miRNAs Are Pharmacodynamic Biomarkers Associated With Therapeutic Response in Pediatric Inflammatory Bowel Disease

Batra

Heier

Diaz-Calderon

et al. 2020

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

show abstract

“…Recently, we found that serum expression of miR-146b-5p was elevated in patients with IBD and changed according to disease activity. A CD miRNA classifier was built that combined the serum miR-146b-5p level and platelet count, and the classifier exhibited higher accuracy in identifying mucosal active CD with a sensitivity of 84.9% and a specificity of 84.6% than using serum miR-146b-5p alone, or CRP alone and thus may be of value for monitoring disease activity (123). Larger cohort studies to verify these results and identify more promising miRNAs for monitoring IBD may be warranted.…”

Section: Serum Micrornasmentioning

confidence: 99%

Serum Biomarkers for Inflammatory Bowel Disease

et al. 2020

Self Cite

View full text Add to dashboard Cite

Background: Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is a chronic, inflammatory disorder of the gastrointestinal tract. As the novel therapeutic goal and biologicals are widely recognized, accurate assessment of disease and prediction of therapeutic response have become a crucial challenge in clinical practice. Also, because of the continuously rising incidence, convenient and economical methods of diagnosis and clinical assessment are urgently needed. Recently, serum biomarkers have made a great progress and become a focus in IBD study because they are non-invasive, convenient, and relatively inexpensive than are markers in biopsy tissue, stool, breath, and other body fluids. Aims: To review the available data on serological biomarkers for IBD. Methods: We searched PubMed using predefined key words on relevant literatures of serum biomarkers regarding diagnosis, evaluation of therapeutic efficacy, surveillance of disease activity, and assessment of prognosis for IBD. Results: We reviewed serological biomarkers that are well-established and widely used (e.g., C-reactive protein), newly discovered biomarkers (e.g., cytokines, antibodies, and non-coding RNAs), and also recently advancements in serological biomarkers (e.g., metabolomics and proteomics) that are used in different aspects of IBD management. Conclusions: With such a wealth of researches, to date, there are still no ideal serum biomarkers for IBD. Serum profiling and non-coding RNAs are just starting to blossom but reveal great promise for future clinical practice. Combining different biomarkers can be valuable in improving performance of disease evaluation.

show abstract

“…An overexpression of miR-146b has also been reported in the inflamed colonic mucosa of CD patients compared to the uninflamed colonic mucosa of both CD patients and control subjects [37]. The level of this miRNA was also increased in the serum of IBD patients compared to healthy subjects [38]. In AIEC LF82-infected compared with uninfected M cells, 38 miRNAs were upregulated and 23 were downregulated.…”

Section: Discussionmentioning

confidence: 86%

Differential miRNA-Gene Expression in M Cells in Response to Crohn’s Disease-Associated AIEC

et al. 2020

View full text Add to dashboard Cite

Adherent-invasive Escherichia coli (AIEC), which abnormally colonize the ileal mucosa of Crohn’s disease (CD) patients, are able to invade intestinal epithelial cells (IECs) and translocate through M cells overlying Peyer’s patches. The levels of microRNA (miRNA) and gene expression in IECs and M cells upon AIEC infection have not been investigated. Here, we used human intestinal epithelial Caco-2 monolayers and an in vitro M-cell model of AIEC translocation to analyze comprehensive miRNA and gene profiling under basal condition and upon infection with the reference AIEC LF82 strain. Our results showed that AIEC LF82 translocated through M cells but not Caco-2 monolayers. Both differential gene expression and miRNA profile in M cells compared to Caco-2 cells were obtained. In addition, AIEC infection induces changes in gene and miRNA profiles in both Caco-2 and M cells. In silico analysis showed that certain genes dysregulated upon AIEC infection were potential targets of AIEC-dysregulated miRNAs, suggesting a miRNA-mediated regulation of gene expression during AIEC infection in Caco-2, as well as M cells. This study facilitates the discovery of M cell-specific and AIEC response-specific gene-miRNA signature and enhances the molecular understanding of M cell biology under basal condition and in response to infection with CD-associated AIEC.

show abstract

Circulating microRNA146b‐5p is superior to C‐reactive protein as a novel biomarker for monitoring inflammatory bowel disease

Cited by 34 publications

References 56 publications

Serum miRNAs Are Pharmacodynamic Biomarkers Associated With Therapeutic Response in Pediatric Inflammatory Bowel Disease

Serum miRNAs Are Pharmacodynamic Biomarkers Associated With Therapeutic Response in Pediatric Inflammatory Bowel Disease

Serum Biomarkers for Inflammatory Bowel Disease

Differential miRNA-Gene Expression in M Cells in Response to Crohn’s Disease-Associated AIEC

Contact Info

Product

Resources

About